Figure 1From: Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scidmiceCytotoxicity of rituximab and gemcitabine. WSU-FSCCL or DoHH2 cells incubated with varying concentrations of gemcitabine, and 4 hr later ± 20 μg/ml rituximab. Cytotoxicity is expressed as percentage of untreated control cells at 72 hr.Back to article page